Previous close | 1.9000 |
Open | 1.8400 |
Bid | 1.8500 x 800 |
Ask | 1.8900 x 1800 |
Day's range | 1.8400 - 1.9200 |
52-week range | 1.0800 - 3.5800 |
Volume | |
Avg. volume | 487,635 |
Market cap | 158.191M |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6380 |
Earnings date | 17 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.50 |
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well as development, commercial, and sales-based milestone payments- -In the United States, the New Drug Application (NDA) for linzagolix is currently under review by the Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) target acti
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc.